Design Therapeutics, Inc. (NASDAQ:DSGN) Director Sells $23,863.62 in Stock

Design Therapeutics, Inc. (NASDAQ:DSGN) Director Deepa Prasad sold 3,806 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $6.27, for a total transaction of $23,863.62. Following the completion of the sale, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $125,400. This represents a 15.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Design Therapeutics Price Performance

Shares of NASDAQ DSGN opened at $6.25 on Friday. Design Therapeutics, Inc. has a 1 year low of $2.24 and a 1 year high of $7.77. The stock has a market capitalization of $353.88 million, a P/E ratio of -7.35 and a beta of 1.86. The company’s 50-day moving average is $5.90 and its 200 day moving average is $4.98.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in DSGN. Virtu Financial LLC lifted its stake in shares of Design Therapeutics by 318.8% in the 3rd quarter. Virtu Financial LLC now owns 46,356 shares of the company’s stock valued at $249,000 after purchasing an additional 35,286 shares during the period. Barclays PLC raised its holdings in Design Therapeutics by 34.2% in the third quarter. Barclays PLC now owns 96,635 shares of the company’s stock worth $520,000 after purchasing an additional 24,602 shares in the last quarter. Geode Capital Management LLC raised its holdings in Design Therapeutics by 7.1% in the third quarter. Geode Capital Management LLC now owns 758,550 shares of the company’s stock worth $4,081,000 after purchasing an additional 50,579 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its position in Design Therapeutics by 58.3% during the third quarter. Frazier Life Sciences Management L.P. now owns 1,892,547 shares of the company’s stock valued at $10,182,000 after buying an additional 697,368 shares during the period. Finally, Point72 Asset Management L.P. boosted its holdings in shares of Design Therapeutics by 61.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,740 shares of the company’s stock valued at $8,612,000 after buying an additional 609,939 shares in the last quarter. Hedge funds and other institutional investors own 56.64% of the company’s stock.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.